AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02598427
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
Trial: NCT04500704
Drug: Almonertinib plus carboplatin and pemetrexed
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Trial: NCT02147873
Drug: birinapant
RxNorm normalized name: Birinapant
DrugBank: Birinapant (DB11782)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03775824
Drug: TNF start
RxNorm normalized name: Star Anise Oil
DrugBank: Anise oil (DB15776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
Trial: NCT02147873
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04389710
Drug: Convalescent Plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
Trial: NCT01358357
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
Trial: NCT00425230
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00758030
Drug: Paliperidone ER OROS
RxNorm normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02473354
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
Trial: NCT02473354
Drug: Carbon dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
Trial: NCT01568931
Drug: Urokinase
RxNorm normalized name: Urokinase
DrugBank: Urokinase (DB00013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intracoronary, urokinase, 200,000 Units, bolus
Trial: NCT01568931
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intracoronary, saline, bolus 1 cc
Trial: NCT00763347
Drug: SYR-619
RxNorm normalized name: petrolatum 0.619 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00763347
Drug: SYR-619
RxNorm normalized name: petrolatum 0.619 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00763347
Drug: SYR-619
RxNorm normalized name: petrolatum 0.619 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00763347
Drug: SYR-619
RxNorm normalized name: petrolatum 0.619 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00763347
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT02481635
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02481635
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00694759
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg for 2 weeks, then 45 mg daily
Trial: NCT00694759
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg twice daily for 1 week, then 1000 mg twice daily
Trial: NCT00199355
Drug: Istradefylline (KW-6002)
RxNorm normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01066754
Drug: Fexofenadine
RxNorm normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine Hydrochloride 180 mg Tablets
Trial: NCT00923351
Drug: rhIL-7
RxNorm normalized name: rhIL-7-hyFc
DrugBank: Efineptakin alfa (DB16395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
Trial: NCT00974012
Drug: Divalproex Sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg ER Tablet
Trial: NCT00093613
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04357015
Drug: intravenous tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
Trial: NCT01951677
Drug: HBsAg
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hepatitis B vaccine antigen
Trial: NCT04357015
Drug: intravenous carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
Trial: NCT01144442
Drug: Hyperthermic intraperitoneal chemotherapy with Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin at a dose of 1000mg/m\^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
Trial: NCT01144442
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
Trial: NCT01144442
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
Trial: NCT01497262
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
Trial: NCT04251364
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily acetazolamide pill intake
Trial: NCT04251364
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily atorvastatin pill intake
Trial: NCT03845387
Drug: KDT-3594
RxNorm normalized name: KDT-3594
DrugBank: KDT-3594 (DB17085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, dose titration
Trial: NCT03845387
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ER formulation, oral administration, dose titration
Trial: NCT01169701
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
Trial: NCT01169701
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
Trial: NCT03076957
Drug: CKD-516 Tablet
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
Trial: NCT01237535
Drug: Luteal support with progesterone only
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
Trial: NCT01237535
Drug: Luteal support with estrogen + progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Luteal support with estrogen + progesterone \[(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg\].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
Trial: NCT04926532
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab is a humanized anti-PD-1 monoclonal antibody
Trial: NCT04926532
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is a multi-kinase inhibitor
Trial: NCT05190952
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
Trial: NCT05190952
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
Trial: NCT05190952
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
Trial: NCT03146663
Drug: NUC-1031 500 mg
RxNorm normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
Trial: NCT03146663
Drug: NUC-1031 750mg
RxNorm normalized name: NUC-7738
DrugBank: NUC-7738 (DB19148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
Trial: NCT02655757
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg, 1 tablet per day for 12 months
Trial: NCT04982055
Drug: Nadroparin (intravenous Infusion)
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous route of administration over a 4-hours infusion of nadroparin 3800 IU
Trial: NCT04982055
Drug: Nadroparin (subcutaneous group)
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous route of administration of nadroparin 3800 IU
Trial: NCT02374645
Drug: Volitinib
RxNorm normalized name: Volitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg or 800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT02374645
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Trial: NCT00978068
Drug: Lopinavir/Ritonavir (LPV/r)
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00978068
Drug: Nevirapine (NVP)
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP will be used for children \< 3 years of age
Trial: NCT00978068
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EFV for children ≥3 years of age
Trial: NCT00978068
Drug: 2 nucleoside reverse transcriptase inhibitor (NRTI)
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin \< 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
Trial: NCT05083793
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The effect of pregabalin on post-operative pain
Trial: NCT01423695
Drug: paclitaxel plus trastuzumab
RxNorm normalized name: Paclitaxel
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
Trial: NCT01352988
Drug: Fumaric acid esters
RxNorm normalized name: Fumaric acid monomethyl ester
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
Trial: NCT00651014
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
Trial: NCT00386087
Drug: Enzastaurin Hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00263068
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day
Trial: NCT01103609
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet od on Day 4
Trial: NCT00264355
Drug: cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00471848
Drug: rabbit antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 vials/10kg daily for 5 days
Trial: NCT00698581
Drug: Brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
Trial: NCT00698581
Drug: Brivaracetam
RxNorm normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
Trial: NCT01536314
Drug: Memantine EBIXA®
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
Trial: NCT00642668
Drug: methoxy polyethylene glycol-epoetin beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
Trial: NCT00077103
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin IV over 30-60 minutes on day 1
Trial: NCT00077103
Drug: fosbretabulin disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
Trial: NCT03022292
Drug: Aflibercept Ophthalmic
RxNorm normalized name: aflibercept ophthalmic
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
Trial: NCT01523886
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
Trial: NCT01523886
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous use: 0,3 mg/kg followed by NaCl-infusion
Trial: NCT01290146
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min
Trial: NCT02567799
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart.
Trial: NCT03309358
Drug: Inhaled SNSP113
RxNorm normalized name: SNSP113
DrugBank: SNSP113 (DB17910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
Trial: NCT04546347
Drug: AZD9833 film-coated tablet B Dose 1
RxNorm normalized name: sennosides, USP
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AZD9833 film-coated tablet B Dose 1
Trial: NCT04546347
Drug: AZD9833 film-coated tablet B Dose 2
RxNorm normalized name: sennosides, USP
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 1 of film-coated tablet B Dose 2
Trial: NCT00657241
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00657241
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01978028
Drug: ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03089203
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2/day given over 3 days
Trial: NCT01536379
Drug: Belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
Trial: NCT00001749
Drug: Antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001749
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01272609
Drug: Timolol + LCP
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
Trial: NCT02809690
Drug: 18F-FMAU
RxNorm normalized name: 18F-FMAU
DrugBank: 5-methyl-2'-fluoroarauracil F-18 (DB14913)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT